Beyond Air, Inc. (XAIR)
| Market Cap | 12.12M |
| Revenue (ttm) | 4.78M |
| Net Income (ttm) | -42.12M |
| Shares Out | 5.23M |
| EPS (ttm) | -10.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 426,610 |
| Open | 2.300 |
| Previous Close | 2.210 |
| Day's Range | 2.250 - 2.330 |
| 52-Week Range | 2.020 - 13.522 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+374.14%) |
| Earnings Date | Aug 12, 2025 |
About XAIR
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for ... [Read more]
Financial Performance
In 2024, Beyond Air's revenue was $3.71 million, an increase of 219.67% compared to the previous year's $1.16 million. Losses were -$46.63 million, -22.60% less than in 2023.
Financial StatementsAnalyst Summary
According to one analyst, the rating for XAIR stock is "Strong Buy" and the 12-month stock price target is $11.0.
News
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnes...
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan
These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people These recent LungFit PH international agreements bring the ex-U...
Beyond Air, Inc. (XAIR) Q1 2026 Earnings Call Transcript
Beyond Air, Inc. (NASDAQ:XAIR) Q1 2026 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Douglas Quinton Larson - Chief Financial Officer Steven Adam Lisi - CEO & Chairman of t...
Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.
GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript
Beyond Air, Inc. (NASDAQ:XAIR) Q4 2025 Earnings Conference Call June 17, 2025 4:30 PM ET Company Participants Douglas Quinton Larson - CFO, Principal Financial Officer & Principal Accounting Officer ...
Beyond Air Stock Dips After Mixed Q4 Results: Here's What To Know
Beyond Air, Inc. XAIR released its fourth-quarter results after Tuesday's closing bell. Here's a look at the key figures from the quarter.
Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and int...
Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH
LungFit PH II's smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the count...
Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings
Beyond Air, Inc. XAIR will release its fourth-quarter financial results after the closing bell on Tuesday, June 17.
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessi...
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
The FDA d esignation m arks a s ignificant m ilestone in the d evelopment of a n ovel t reatment for a r are n eurodevelopmental d isorder
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board
Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer's Disease Professor Shechtman joins f...
Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home
GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnes...
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site
As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO techno...
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy
First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation devel...
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH
Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH syst...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnes...
Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript
Beyond Air, Inc. (NASDAQ:XAIR) Q3 2025 Results Conference Call February 10, 2025 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Exe...
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH ® in Europe and Market Authorization in Australia; internation...
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia
GARDEN CITY, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products
In a Fast-Track SWIFT challenge brought by competitor Vero Biotech, Inc., BBB National Programs' National Advertising Division recommended that Beyond Air, Inc. discontinue the challenged comparative ...
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for soli...